Eduardo Vilar-Sanchez, M.D., Ph.D.

Peer-Reviewed Articles

1. Tripathi C, Tovar Perez JE, Kapoor S, Muhsin A, Dashwood WM, Demirhan Y, Demirhan M, Shapiro A, Mohammed A, Sei S, Thompson J, Zaheer M, Sinha KM, Brown PH, Savage MI, Vilar E, Rajendran P, Dashwood RH. Antitumor efficacy of intermittent low-dose erlotinib plus sulindac via MHC upregulation and remodeling of the immune cell niche. Int J Cancer, 2025. e-Pub 2025. PMID: 40072251.
2. Bowen CM, Duzagac F, Martel-Martel A, Reyes-Uribe L, Zaheer M, Thompson J, Deng N, Sinha R, Mazumdar S, Taggart MW, Jain AK, Edelmann W, Sinha KM, Vilar E. Inhibition of histone methyltransferase EZH2 for immune-interception of colorectal cancer in Lynch syndrome. JCI Insight, 2025. e-Pub 2025. PMID: 39946195.
3. Alshenaifi JY, Vetere G, Maddalena G, Yousef M, White MG, Shen JP, Vilar E, Parseghian C, Dasari A, Morris VK, Huey R, Overman MJ, Wolff R, Raghav KP, Willis J, Alfaro K, Futreal A, You YN, Kopetz S. Mutational and co-mutational landscape of early onset colorectal cancer. Biomarkers 30(1):64-76, 2025. e-Pub 2025. PMID: 39761813.
4. Yousef M, Yousef A, Chowdhury S, Fanaeian MM, Knafl M, Peterson J, Zeineddine M, Alfaro K, Zeineddine F, Goldstein D, Hornstein N, Dasari A, Huey R, Johnson B, Higbie V, Bent A, Kee B, Lee M, Morelli MP, Morris VK, Halperin D, Overman MJ, Parseghian C, Vilar E, Wolff R, Raghav KP, White MG, Uppal A, Sun R, Wang W, Kopetz S, Willis J, Shen JP. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncol 10(11), 2024. e-Pub 2024. PMID: 39264607.
5. Serrano D, Johansson H, Bertelsen BE, Gandini S, Mellgren G, Thomas P, Crew KD, Kumar NB, Macis D, Aristarco V, Guerrieri-Gonzaga A, Lazzeroni M, D'Amico M, Buttiron-Webber T, Briata IM, Spinaci S, Galimberti V, Vornik LA, Vilar-Sanchez E, Brown PH, Heckman-Stoddard BM, Szabo E, Bonanni B, Decensi A. Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedules. J Natl Cancer Inst. e-Pub 2024. PMID: 39110531.
6. Meuser E, Chang K, Walters A, Hurley JJ, West HD, Perry I, Mort M, Reyes-Uribe L, Truscott R, Jones N, Lawrence R, Jenkins G, Giles P, Dolwani S, Al-Sarireh B, Hawkes N, Short E, Williams GT, Taggart MW, Luetchford K, Lynch PM, Terlouw D, Nielsen M, Walton SJ, Latchford A, Clark SK, Sampson JR, Vilar E, Thomas LE. PIGA mutations and glycosylphosphatidylinositol anchor dysregulation in polyposis-associated duodenal tumorigenesis. Mol Cancer Res 22(6):515-523, 2024. e-Pub 2024. PMID: 38546397.
7. Bolivar AM, Duzagac F, Deng N, Reyes-Uribe L, Chang K, Wu W, Bowen CM, Taggart MW, Thirumurthi S, Lynch PM, You YN, Rodriguez-Pascual J, Lipkin SM, Kopetz S, Scheet P, Lizee GA, Reuben A, Sinha KM, Vilar E. Genomic Landscape of Lynch Syndrome Colorectal Neoplasia Identifies Shared Mutated Neoantigens for Immunoprevention. Gastroenterology 166(5):787-801.e11, 2024. e-Pub 2024. PMID: 38244726.
8. Deng N, Sinha KM, Vilar E. MONET: a database for prediction of neoantigens derived from microsatellite loci. Front Immunol 15:1394593, 2024. e-Pub 2024. PMID: 38835776.
9. Baydogan S, Mohindroo C, Hasanov M, Montiel MF, Quesada P, Cazacu IM, Luzuriaga Chavez AA, Mork ME, Dong W, Feng L, You YN, Arun B, Vilar E, Brown P, Katz MHG, Chari ST, Maitra A, Tamm EP, Kim MP, Bhutani MS, McAllister F. New-onset diabetes is a predictive risk factor for pancreatic lesions in high-risk individuals: An observational cohort study. Endosc Ultrasound 13(2):83-88, 2024. e-Pub 2024. PMID: 38947744.
10. Simmons, K, Thomas, J, Ludford, K, Willis, JA, Serpas Higbie, V, Raghav, KS, Johnson, B, Dasari, NV, Kee, BK, Parseghian, C, Lee, MS, Le, PH, Morelli, MP, Shen, JY, Bent, AH, Vilar Sanchez, E, Wolff, RA, Kopetz, S, Overman, MJ, Morris, VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Research Communications 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
11. Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
12. Annapragada A, Sikora AG, Marathe H, Liu S, Demetriou M, Fong L, Gao J, Kufe D, Morris ZS, Vilar E, Sharon E, Hutson A, Odunsi K. The Cancer Moonshot Immuno-Oncology Translational Network (IOTN) at age 5: Accelerating Cancer Immunotherapies. J Natl Cancer Inst 115(11):1262-1270, 2023. e-Pub 2023. PMID: 37572314.
13. Deng N, Reyes-Uribe L, Fahrmann JF, Thoman WS, Munsell MF, Dennison JB, Murage E, Wu R, Hawk ET, Thirumurthi S, Lynch PM, Dieli-Conwright CM, Lazar AJ, Jindal S, Chu K, Chelvanambi M, Basen-Engquist K, Li Y, Wargo JA, McAllister F, Allison JP, Sharma P, Sinha KM, Hanash S, Gilchrist SC, Vilar E. Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-associated Immunity in Lynch Syndrome. Clin Cancer Res 29(21):4361-4372, 2023. e-Pub 2023. PMID: 37724990.
14. Poplaski V, Bomidi C, Kambal A, Nguyen-Phuc H, Di Rienzi SC, Danhof HA, Zeng XL, Feagins LA, Deng N, Vilar E, McAllister F, Coarfa C, Min S, Kim HJ, Shukla R, Britton R, Estes MK, Blutt SE. Human intestinal organoids from Cronkhite-Canada syndrome patients reveal link between serotonin and proliferation. J Clin Invest 133(21):e166884, 2023. e-Pub 2023. PMID: 37909332.
15. Rodgers-Fouche L, Arora S, Ricker C, Li D, Farooqi M, Balaguer F, Dominguez-Valentin M, Guillem JG, Kanth P, Liska D, Melson J, Mraz KA, Shirts BH, Vilar E, Katona BW, Hodan R. Exploring Stakeholders' Perspectives on Implementing Universal Germline Testing for Colorectal Cancer: Findings From a Clinical Practice Survey. JCO Precis Oncol 7:e2300440, 2023. e-Pub 2023. PMID: 37897815.
16. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol 41(12):JCO2201351, 2023. e-Pub 2023. PMID: 36623241.
17. You YN, Moskowitz JB, Chang GJ, Mork ME, Rodriguez-Bigas MA, Bednarski BK, Messick CA, Tillman MM, Skibber JM, Nguyen ST, Kopetz S, Vilar E. Germline Cancer Risk Profiles of Young-Onset Colorectal Cancer Patients: Findings from a Prospective Universal Germline Testing and Tele-Genetics Program. Dis Colon Rectum 66(4):531-542, 2023. e-Pub 2023. PMID: 35195555.
18. Cavestro GM, Mannucci A, Balaguer F, Hampel H, Kupfer SS, Repici A, Sartore-Bianchi A, Seppälä TT, Valentini V, Boland CR, Brand RE, Buffart TE, Burke CA, Caccialanza R, Cannizzaro R, Cascinu S, Cercek A, Crosbie EJ, Danese S, Dekker E, Daca-Alvarez M, Deni F, Dominguez-Valentin M, Eng C, Goel A, Guillem JG, BBSL H, Kahi C, Kalady MF, Kastrinos F, Kühn F, Laghi L, Latchford A, Liska D, Lynch P, Malesci A, Mauri G, Meldolesi E, Møller P, Monahan KJ, Möslein G, Murphy CC, Nass K, Ng K, Oliani C, Papaleo E, Patel SG, Puzzono M, Remo A, Ricciardiello L, Ripamonti CI, Siena S, Singh SK, Stadler ZK, Stanich PP, Syngal S, Turi S, Urso ED, Valle L, Vanni VS, Vilar E, Vitellaro M, You YN, Yurgelun MB, Zuppardo RA, Stoffel EM, Ereditarietà Tumori AIF, Gastrointestinal Cancer CGOTAOI, Tumour Group EH, Hereditary Tumours ATISFG. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines. Clin Gastroenterol Hepatol 21(3):581-603.e33, 2023. e-Pub 2023. PMID: 36549470.
19. Samadder NJ, Foster N, McMurray RP, Burke CA, Stoffel E, Kanth P, Das R, Cruz-Correa M, Vilar E, Mankaney G, Buttar N, Thirumurthi S, Turgeon DK, Sossenheimer M, Westover M, Richmond E, Umar A, Della'Zanna G, Rodriguez LM, Szabo E, Zahrieh D, Limburg PJ. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis. Gut 72(2):256-263, 2023. e-Pub 2023. PMID: 35636921.
20. Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol 41(3):101200JCO2201423, 2023. e-Pub 2023. PMID: 36351210.
21. Mraz KA, Hodan R, Rodgers-Fouche L, Arora S, Balaguer F, Guillem JG, Jeter JM, Kanth P, Li D, Liska D, Melson J, Perez K, Ricker C, Shirts BH, Vilar E, Katona BW, Dominguez-Valentin M. Current chemoprevention approaches in Lynch syndrome and Familial adenomatous polyposis: a global clinical practice survey. Front Oncol 13:1141810, 2023. e-Pub 2023. PMID: 37293588.
22. Bowen CM, Deng N, Reyes-Uribe L, Parra ER, Rocha P, Solis LM, Wistuba II, Sepeda VO, Vornik L, Perloff M, Szabo E, Umar A, Sinha KM, Brown PH, Vilar E. Naproxen chemoprevention induces proliferation of cytotoxic lymphocytes in Lynch Syndrome colorectal mucosa. Front Immunol 14:1162669, 2023. e-Pub 2023. PMID: 37207208.
23. Del Carmen G, Reyes-Uribe L, Goyco D, Evans K, Bowen CM, Kinnison JL, Sepeda VO, Weber DM, Moskowitz J, Mork ME, Thirumurthi S, Lynch PM, Rodriguez-Bigas MA, Taggart MW, You YN, Vilar E. Colorectal surveillance outcomes from an institutional longitudinal cohort of lynch syndrome carriers. Front Oncol 13:1146825, 2023. e-Pub 2023. PMID: 37168379.
24. Peacock O, Vilar E, Guraieb-Trueba M, Thirumurthi S, Chang GJ, You YN. Clinically Significant Metachronous Colorectal Pathology Detected Among Young-Onset Colorectal Cancer Survivors: Implications for Post-Resection Surveillance Guidelines. Gastroenterology 163(6):1682-1684.e2, 2022. e-Pub 2022. PMID: 35987446.
25. Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
26. Hodan R, Rodgers-Fouche L, Arora S, Dominguez-Valentin M, Kanth P, Katona BW, Mraz KA, Roberts ME, Vilar E, Soto-Azghani CM, Brand RE, Esplin ED, Perez K. Patterns of germline and somatic testing after universal tumor screening for Lynch syndrome: A clinical practice survey of active members of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. J Genet Couns 31(4):949-955, 2022. e-Pub 2022. PMID: 35218578.
27. Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 10(8), 2022. e-Pub 2022. PMID: 36007963.
28. Hsieh RC, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, Hsu WH, Lin SH, Hung MC, Chan LC, Bhanu KR, Srinivasamani A, De Azevedo RA, Chou YC, DePinho RA, Gubin M, Vilar E, Chen CH, Slay R, Jayaprakash P, Hegde SM, Hartley G, Lea ST, Prasad R, Morrow B, Couillault CA, Steiner M, Wang CC, Venkatesulu BP, Taniguchi C, Kim YSB, Chen J, Rudqvist NP, Curran MA. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol 7(72):eabl9330, 2022. e-Pub 2022. PMID: 35687697.
29. Rogers JE, Woodard TL, Gonzalez GM, Dasari A, Johnson B, Morris VK, Kee B, Vilar E, Nancy You Y, Chang GJ, Bednarski B, Skibber JM, Rodriguez-Bigas MA, Eng C. Colorectal cancer during pregnancy or postpartum: Case series and literature review. Obstet Med 15(2):118-124, 2022. e-Pub 2022. PMID: 35845232.
30. Schiller JT, Lowy DR, Frazer IH, Finn OJ, Vilar E, Lyerly HK, Gnjatic S, Zaidi N, Ott PA, Balachandran VP, Dietrich PY, Migliorini D, Vonderheide RH, Domchek SM. Cancer vaccines. Cancer Cell 40(6):559-564, 2022. e-Pub 2022. PMID: 35700704.
31. Orouji E, Raman AT, Singh AK, Sorokin A, Arslan E, Ghosh AK, Schulz J, Terranova C, Jiang S, Tang M, Maitituoheti M, Callahan SC, Barrodia P, Tomczak K, Jiang Y, Jiang Z, Davis JS, Ghosh S, Lee HM, Reyes-Uribe L, Chang K, Liu Y, Chen H, Azhdarinia A, Morris J, Vilar E, Carmon KS, Kopetz SE, Rai K. Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Gut 71(5):938-949, 2022. e-Pub 2022. PMID: 34059508.
32. Samimi G, House M, Benante K, Bengtson L, Budd T, Dermody B, DeShong K, Dyer V, Kimler BF, Sahasrabuddhe VV, Siminski S, Ford LG, Vilar E, Szabo E. Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs. Cancer Prev Res (Phila) 15(5):279-284, 2022. e-Pub 2022. PMID: 35502553.
33. Ozirmak Lermi N, Gray SB, Bowen CM, Reyes-Uribe L, Dray BK, Deng N, Harris RA, Raveendran M, Benavides F, Hodo CL, Taggart MW, Colbert Maresso K, Sinha KM, Rogers J, Vilar E. Comparative molecular genomic analyses of a spontaneous rhesus macaque model of mismatch repair-deficient colorectal cancer. PLoS Genet 18(4):e1010163, 2022. e-Pub 2022. PMID: 35446842.
34. Lopez A, Reyna DE, Gitego N, Kopp F, Zhou H, Miranda-Roman MA, Nordstrøm LU, Narayanagari SR, Chi P, Vilar E, Tsirigos A, Gavathiotis E. Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. Nat Commun 13(1):1199, 2022. e-Pub 2022. PMID: 35256598.
35. Basen-Engquist K, Raber M, Strong LL, Schembre S, Li L, Arun B, Lu K, You N, Vilar E, Lynch P, Fares S, Peterson SK. Optimization of an mHealth lifestyle intervention for families with hereditary cancer syndromes: Study protocol for a multiphase optimization strategy feasibility study. Contemp Clin Trials 113:106662, 2022. e-Pub 2021. PMID: 34971795.
36. Liang S, Willis J, Dou J, Mohanty V, Huang Y, Vilar E, Chen K. Sensei: how many samples to tell a change in cell type abundance?. BMC Bioinformatics 23(1):2, 2022. e-Pub 2022. PMID: 34983369.
37. Chang K, McAllister F, Vilar E. Transcriptomic-Assisted Immune and Neoantigen Profiling in Premalignancy. Methods Mol Biol 2435:95-105, 2022. e-Pub 2022. PMID: 34993941.
38. Tosti E, Almeida AS, Tran TTT, Barbachan E Silva M, PÓ B, Dubin R, Chen K, Beck AP, Mclellan AS, Vilar E, Golden A, O'Toole PW, Edelmann W. Loss of MMR and TGFBR2 Increases the Susceptibility to Microbiota-Dependent Inflammation-Associated Colon Cancer. Cell Mol Gastroenterol Hepatol 14(3):693-717, 2022. e-Pub 2022. PMID: 35688320.
39. Gebert J, Gelincik O, Oezcan-Wahlbrink M, Marshall JD, Hernandez-Sanchez A, Urban K, Long M, Cortes E, Tosti E, Katzenmaier EM, Song Y, Elsaadi A, Deng N, Vilar E, Fuchs V, Nelius N, Yuan YP, Ahadova A, Sei S, Shoemaker RH, Umar A, Wei L, Liu S, Bork P, Edelmann W, von Knebel Doeberitz M, Lipkin SM, Kloor M. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gastroenterology 161(4):1288-1302.e13, 2021. e-Pub 2021. PMID: 34224739.
40. Bowen CM, Walter L, Borras E, Wu W, Ozcan Z, Chang K, Bommi PV, Taggart MW, Thirumurthi S, Lynch PM, Reyes-Uribe L, Scheet PA, Sinha KM, Vilar E. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Cancer Prev Res (Phila) 14(9):851-862, 2021. e-Pub 2021. PMID: 34266857.
41. Chakravarti D, Lee R, Multani AS, Santoni A, Keith Z, Hsu WH, Chang K, Reyes L, Rashid A, Wu CJ, Li J, Zhang J, Shim HS, Chandra K, Deng P, Spring DJ, Nielsen OH, Riis LB, Mayigegowda KK, Blutt SE, Zhang J, Younes M, DuPont A, Thirumurthi S, Vilar E, Estes MK, Colla S, Shroyer NF, DePinho RA. Telomere dysfunction instigates inflammation in inflammatory bowel disease. Proceedings Natl Acad Sci U S A 118(29), 2021. e-Pub 2021. PMID: 34253611.
42. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer 20(2):137-147.e1, 2021. e-Pub 2021. PMID: 33229221.
43. Bommi PV, Bowen CM, Reyes-Uribe L, Wu W, Katayama H, Rocha P, Parra ER, Francisco-Cruz A, Ozcan Z, Tosti E, Willis JA, Wu H, Taggart MW, Burks JK, Lynch PM, Edelmann W, Scheet PA, Wistuba II, Sinha KM, Hanash SM, Vilar E. The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells. Cancer Res 81(10):2760-2773, 2021. e-Pub 2021. PMID: 34003775.
44. Ulusan AM, Rajendran P, Dashwood WM, Yavuz OF, Kapoor S, Gustafson TA, Savage MI, Brown PH, Sei S, Mohammed A, Vilar E, Dashwood RH. Optimization of erlotinib plus sulindac dosing regimens for intestinal cancer prevention in an Apc-mutant model of Familial Adenomatous Polyposis. Cancer Prev Res (Phila) 14(3):325-336, 2021. e-Pub 2021. PMID: 33277315.
45. Reyes-Uribe L, Wu W, Gelincik O, Bommi PV, Francisco-Cruz A, Solis LM, Lynch PM, Lim R, Stoffel EM, Kanth P, Samadder NJ, Mork ME, Taggart MW, Milne GL, Marnett LJ, Vornik L, Liu DD, Revuelta M, Chang K, You YN, Kopelovich L, Wistuba II, Lee JJ, Sei S, Shoemaker RH, Szabo E, Richmond E, Umar A, Perloff M, Brown PH, Lipkin SM, Vilar E. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut 70(3):555-566, 2021. e-Pub 2021. PMID: 32641470.
46. Miller MS, Allen PJ, Brown PH, Chan AT, Clapper ML, Dashwood RH, Demehri S, Disis ML, DuBois RN, Glynn RJ, Kensler TW, Khan SA, Johnson BD, Liby KT, Lipkin SM, Mallery SR, Meuillet EJ, Roden RBS, Schoen RE, Sharp ZD, Shirwan H, Siegfried JM, Rao CV, You M, Vilar E, Szabo E, Mohammed A. Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. J Cancer Prev 26(1):71-82, 2021. e-Pub 2021. PMID: 33842408.
47. Collaborative Group on Duodenal Polyposis in MAP, Thomas LE, Hurley JJ, Sanchez AA, Aznárez MR, Backman AS, Bjork J, Capella G, Clark SK, Colas C, Dekker E, Dolwani S, Ghorbanoghli Z, Gonn M, Gonzalez Romero S, Hes FJ, Jundi H, Kelland S, Latchford AR, Brito HL, Lynch PM, Meuser E, Mork ME, Mort M, Garcia MN, Nielsen M, Parc Y, Ricci MT, Saurin JC, Tuin KV, Vasen H, E V, Vinet O, Vitellaro M, Walton SJ, West HD, Sampson JR. Duodenal adenomas and cancer in MUTYH-associated polyposis: an international cohort study. Gastroenterology 160(3):952-954.e4, 2021. e-Pub 2021. PMID: 33130102.
48. Jácome AA, Vreeland TJ, Johnson B, Kawaguchi Y, Wei SH, Nancy You Y, Vilar E, Vauthey JN, Eng C. The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. Br J Cancer 124(4):797-804, 2021. e-Pub 2021. PMID: 33208919.
49. Williams D, E V, Shakrukh Hashmi S, Choates M, Noblin S, Mork M. Somatic mismatch repair testing in evaluation of Lynch syndrome: The gap between preferred and current practices. J Genet Couns 29(5):728-736, 2020. e-Pub 2020. PMID: 31896172.
50. Chakravarti D, Hu B, Mao X, Rashid A, Li J, Li J, Liao WT, Whitley EM, Dey P, Hou P, LaBella KA, Chang A, Wang G, Spring DJ, Deng P, Zhao D, Liang X, Lan Z, Lin Y, Sarkar S, Terranova C, Deribe YL, Blutt SE, Okhuysen P, Zhang J, Vilar E, Nielsen OH, Dupont A, Younes M, Patel KR, Shroyer NF, Rai K, Estes MK, Wang YA, Bertuch AA, DePinho RA. Telomere dysfunction activates YAP1 to drive tissue inflammation. Nat Commun 11(1):4766, 2020. e-Pub 2020. PMID: 32958778.
51. Lee JJ, Kopetz S, Vilar E, Shen JP, Chen K, Maitra A. Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract. Genes (Basel) 11(6), 2020. e-Pub 2020. PMID: 32545271.
52. Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-Reported Symptom Outcomes and Microsatellite Instability in Patients with Metastatic Colorectal Cancer. Clin Colorectal Cancer 19(1):48-56.e2, 2020. e-Pub 2020. PMID: 32008976.
53. Jakubek YA, Chang K, Sivakumar S, Yu Y, Giordano MR, Fowler J, Huff CD, Kadara H, Vilar E, Scheet P. Large-scale analysis of acquired chromosomal alterations in non-tumor samples from patients with cancer. Nat Biotechnol 38(1):90-96, 2020. e-Pub 2020. PMID: 31685958.
54. Omark J, Vilar E, You YN, Dunnington L, Noblin S, Stevens B, Mork M. Patients with unexplained mismatch repair deficiency are interested in updated genetic testing. Hered Cancer Clin Pract 18:19, 2020. e-Pub 2020. PMID: 32973963.
55. Mork ME, Rodriguez A, Bannon SA, Lynch PM, Rodriguez-Bigas MA, Thirumurthi S, You YN, Vilar E. Outcomes of disease-specific next-generation sequencing gene panel testing in adolescents and young adults with colorectal cancer. Cancer Genet 235-236:77-83, 2019. e-Pub 2019. PMID: 31101557.
56. Delacruz RGC, Sandoval IT, Chang K, Miller BN, Reyes-Uribe L, Borras E, Lynch PM, Taggart MW, Hawk ET, Vilar E, Jones DA. Functional characterization of CNOT3 variants identified in familial adenomatous polyposis adenomas. Oncotarget 10(39):3939-3951, 2019. e-Pub 2019. PMID: 31231471.
57. You YN, Borras E, Chang K, Price BA, Mork M, Chang GJ, Rodriguez-Bigas MA, Bednarski BK, Meric-Bernstam F, Vilar E. Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine. Dis Colon Rectum 62(4):429-437, 2019. e-Pub 2019. PMID: 30730459.
58. Zacharias NM, Ornelas A, Lee J, Hu J, Davis JS, Uddin N, Pudakalakatti S, Menter DG, Karam JA, Wood CG, Hawk ET, Kopetz S, Vilar E, Bhattacharya PK, Millward SW. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl 58(13):4179-4183, 2019. e-Pub 2019. PMID: 30680862.
59. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 30(3):495, 2019. e-Pub 2019. PMID: 29982323.
60. Rajendran P, Johnson G, Li L, Chen YS, Dashwood M, Nguyen N, Ulusan A, Ertem F, Zhang M, Li J, Sun D, Huang Y, Wang S, Leung HC, Lieberman D, Beaver L, Ho E, Bedford M, Chang K, Vilar E, Dashwood R. Acetylation of CCAR2 establishes a BET/BRD9 acetyl switch in response to combined deacetylase and bromodomain inhibition. Cancer Res 79(5):918-927, 2019. e-Pub 2019. PMID: 30643017.
61. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge. Ann Oncol 30(2):243-249, 2019. e-Pub 2019. PMID: 30462160.
62. Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol 3:1-10, 2019. e-Pub 2019. PMID: 32914034.
63. Bannon SA, Montiel MF, Goldstein JB, Dong W, Mork ME, Borras E, Hasanov M, Varadhachary GR, Maitra A, Katz MH, Feng L, Futreal A, Fogelman DR, Vilar E, McAllister F. High prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Cancer Prev Res (Phila) 11(11):679-686, 2018. e-Pub 2018. PMID: 30274973.
64. Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol 29(10):2061-2067, 2018. e-Pub 2018. PMID: 30412224.
65. Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol 4(8):1085-1092, 2018. e-Pub 2018. PMID: 29710228.
66. Zhang Y, Zoltan M, Riquelme E, Xu H, Sahin I, Castro-Pando S, Montiel MF, Chang K, Jiang Z, Ling J, Gupta S, Horne W, Pruski M, Wang H, Sun SC, Lozano G, Chiao P, Maitra A, Leach SD, Kolls JK, Vilar E, Wang TC, Bailey JM, McAllister F. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. Gastroenterology 155(1):210-223.e3, 2018. e-Pub 2018. PMID: 29604293.
67. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2018. PMID: 29069279.
68. Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol 24(13):4051-4058, 2017. e-Pub 2017. PMID: 28936799.
69. Gausachs M, Borras E, Chang K, Gonzalez S, Azuara D, Delgado Amador A, Lopez-Doriga A, San Lucas FA, Sanjuan X, Paules MJ, Taggart MW, Davies GE, Ehli EA, Fowler J, Moreno V, Pineda M, You YN, Lynch PM, Lazaro C, Navin NE, Scheet PA, Hawk ET, Capella G, Vilar E. Mutational Heterogeneity in APC and KRAS Arises at the Crypt level and Leads to Polyclonality in Early Colorectal Tumorigenesis. Clin Cancer Res 23(19):5936-5947, 2017. e-Pub 2017. PMID: 28645942.
70. Borras E, Chang K, Pande M, Cuddy A, Bosch JL, Bannon SA, Mork ME, Rodriguez-Bigas MA, Taggart MW, Lynch PM, You YN, Vilar E. In Silico Systems Biology Analysis of Variants of Uncertain Significance in Lynch Syndrome Supports the Prioritization of Functional Molecular Validation. Cancer Prev Res (Phila) 10(10):580-587, 2017. e-Pub 2017. PMID: 28765196.
71. Goldstein JB, Wu W, Borras E, Masand G, Cuddy A, Mork ME, Bannon SA, Lynch PM, Rodriguez-Bigas M, Taggart MW, Wu J, Scheet P, Kopetz S, You YN, Vilar E. Can Microsatellite Status of Colorectal Cancer be Reliably Assessed after Neoadjuvant Therapy?. Clin Cancer Res 23(17):5246-5254, 2017. e-Pub 2017. PMID: 28522602.
72. Leung ML, Davis A, Gao R, Casasent A, Wang Y, Sei E, Vilar E, Maru D, Kopetz S, Navin NE. Single cell DNA sequencing reveals a late-dissemination model in metastatic colorectal cancer. Genome Res 27(8):1287-1299, 2017. e-Pub 2017. PMID: 28546418.
73. Lo YH, Noah TK, Chen MS, Zou W, Borras E, Vilar E, Shroyer NF. SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of β-catenin. Gastroenterology 153(1):205-218.e8, 2017. e-Pub 2017. PMID: 28390865.
74. Maletzki C, Huehns M, Bauer I, Ripperger T, Mork MM, Vilar E, Klöcking S, Zettl H, Prall F, Linnebacher M. Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair-deficiency and Lynch syndrome. Mol Carcinog 56(7):1753-1764, 2017. e-Pub 2017. PMID: 28218421.
75. Mork ME, Rodriguez A, Taggart MW, Rodriguez-Bigas MA, Lynch PM, Bannon SA, You YN, Vilar E. Identification of MSH2 inversion of exons 1-7 in clinical evaluation of families with suspected Lynch syndrome. Fam Cancer 16(3):357-361, 2017. e-Pub 2017. PMID: 28004223.
76. Crespo M, Vilar E, Tsai SY, Chang K, Amin S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, Gordillo M, Xiang JZ, Maxfield FR, Lipkin S, Evans T, Chen S. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat Med 23(7):878-884, 2017. e-Pub 2017. PMID: 28628110.
77. Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawke D, Hawk E, Vilar E, Bhattacharya P, Millward S. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev 36(2):289-303, 2017. e-Pub 2017. PMID: 28762014.
78. Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
79. Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, Vilar E, Song X, Zhang J, Kopetz S, Futreal A, Wang YA, Kwong LN, DePinho RA. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev 31(4):370-382, 2017. e-Pub 2017. PMID: 28289141.
80. Ertem FU, Zhang W, Chang K, Mohaiza Dashwood W, Rajendran P, Sun D, Abudayyeh A, Vilar E, Abdelrahim M, Dashwood RH. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam. Int J Cancer 140(2):460-468, 2017. e-Pub 2017. PMID: 27706811.
81. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One 12(8):e0183949, 2017. e-Pub 2017. PMID: 28850629.
82. San Lucas FA, Sivakumar S, Vattathil S, Fowler J, Vilar E, Scheet P. Rapid and powerful detection of subtle allelic imbalance from exome sequencing data with hapLOHseq. Bioinformatics 32(19):3015-7, 2016. e-Pub 2016. PMID: 27288500.
83. de Rosa N, Rodriguez-Bigas MA, Chang GJ, Veerapong J, Borras E, Krishnan S, Bednarski B, Messick CA, Skibber JM, Feig BW, Lynch PM, Vilar E, You YN. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol 34(25):3039-46, 2016. e-Pub 2016. PMID: 27432916.
84. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
85. Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mork ME, You YN, Taggart MW, McAllister F, Jones DA, Davies GE, Edelmann W, Ehli EA, Lynch PM, Hawk ET, Capella G, Scheet P, Vilar E. Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prev Res (Phila) 9(6):417-27, 2016. e-Pub 2016. PMID: 27221540.
86. Scavo MP, Gentile E, Wolfram J, Gu J, Barone M, Evangelopoulos M, Martinez JO, Liu X, Celia C, Tasciotti E, Vilar E, Shen H. Multistage vector delivery of sulindac and silymarin for prevention of colon cancer. Colloids Surf B Biointerfaces 136:694-703, 2015. e-Pub 2015. PMID: 26513752.
87. Mork ME, You YN, Ying J, Bannon SA, Lynch PM, Rodriguez-Bigas MA, Vilar E. High Prevalence of Hereditary Cancer Syndromes in Adolescents and Young Adults With Colorectal Cancer. J Clin Oncol 33(31):3544-9, 2015. e-Pub 2015. PMID: 26195711.
88. Kneuertz PJ, Chang GJ, Hu CY, Rodriguez-Bigas MA, Eng C, Vilar E, Skibber JM, Feig BW, Cormier JN, You YN. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg 150(5):402-9, 2015. e-Pub 2015. PMID: 25806815.
89. Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
90. Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 112(3):424-8, 2015. e-Pub 2015. PMID: 25535726.
91. San Lucas FA, Fowler J, Chang K, Kopetz S, Vilar E, Scheet P. Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. Mol Cancer Ther 13(12):3230-40, 2014. e-Pub 2014. PMID: 25349306.
92. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 25(10):2008-14, 2014. e-Pub 2014. PMID: 25009008.
93. Vilar E, Mork ME, Cuddy A, Borras E, Bannon SA, Taggart MW, Ying J, Broaddus RR, Luthra R, Rodriguez-Bigas MA, Lynch PM, You YQ. Role of microsatellite instability-low as a diagnostic biomarker of Lynch syndrome in colorectal cancer. Cancer Genet 207(10-12):495-502, 2014. e-Pub 2014. PMID: 25432668.
94. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25(5):1032-8, 2014. e-Pub 2014. PMID: 24585723.
95. Bannon SA, Mork M, Vilar E, Peterson SK, Lu K, Lynch PM, Rodriguez-Bigas MA, You YN. Patient-reported disease knowledge and educational needs in Lynch syndrome: findings of an interactive multidisciplinary patient conference. Hered Cancer Clin Pract 12(1):1, 2014. e-Pub 2014. PMID: 24499499.
96. Vilar E, Grünwald V, Schöffski P, Singer H, Salazar R, Iglesias JL, Casado E, Cullell-Young M, Baselga J, Tabernero J. A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. Invest New Drugs 30(1):299-305, 2012. e-Pub 2012. PMID: 20820909.
97. Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, Gruber SB. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 71(7):2632-42, 2011. e-Pub 2011. PMID: 21300766.
98. Vilar E, Mukherjee B, Kuick R, Raskin L, Misek DE, Taylor JM, Giordano TJ, Hanash SM, Fearon ER, Rennert G, Gruber SB. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res 15(8):2829-39, 2009. e-Pub 2009. PMID: 19351759.
99. Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, Baselga J, Tabernero J. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 99(10):1607-12, 2008. e-Pub 2008. PMID: 18941461.

Invited Articles

1. Haldar SD, Vilar E, Maitra A, Zaidi N. Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention. Cancer Prev Res (Phila) 16(9):483-495, 2023. e-Pub 2023. PMID: 37001882.
2. Boardman LA, Vilar E, You YN, Samadder J. AGA Clinical Practice Update on Young Adult-Onset Colorectal Cancer Diagnosis and Management: Expert Review. Clin Gastroenterol Hepatol 18(11):2415-2424, 2020. e-Pub 2020. PMID: 32525015.
3. Willis JA, Reyes-Uribe L, Chang K, Lipkin SM, Vilar E. Immune Activation in Mismatch Repair Deficient Carcinogenesis: More Than Just Mutational Rate. Clin Cancer Res 26(1):11-17, 2020. e-Pub 2020. PMID: 31383734.
4. Valle L, Vilar E, Tavtigian SV, Stoffel EM. Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol 247(5):574-588, 2019. e-Pub 2019. PMID: 30584801.
5. Lippman SM, Abate-Shen C, Colbert Maresso KL, Colditz GA, Dannenberg AJ, Davidson NE, Disis ML, DuBois RN, Szabo E, Giuliano AR, Hait WN, Lee JJ, Kensler TW, Kramer BS, Limburg P, Maitra A, Martinez ME, Rebbeck TR, Schmitz KH, Vilar E, Hawk ET. AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. Cancer Prev Res (Phila) 11(12):735-778, 2018. e-Pub 2018. PMID: 30530635.
6. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res 77(7):1510-1541, 2017. e-Pub 2017. PMID: 28373404.
7. Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM. Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A 113(39):10750-8, 2016. e-Pub 2016. PMID: 27638202.
8. Vilar E, Tabernero J. Molecular Dissection of Microsatellite Instable Colorectal Cancer. Cancer Discov 3(5):502-11, 2013. e-Pub 2013. PMID: 23454900.
9. Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 10(3):395-403, 2011. e-Pub 2011. PMID: 21216931.
10. Dienstmann R, E V, Tabernero J. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J 17(2):114-26, 2011. e-Pub 2011. PMID: 21427555.
11. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7(3):153-62, 2010. e-Pub 2010. PMID: 20142816.
12. Durán I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, Yao J, Tabernero J. New drug development in digestive neuroendocrine tumors. Ann Oncol 18(8):1307-13, 2007. e-Pub 2007. PMID: 17301070.
13. Vilar E, Calvo E, Tabernero J. Molecular biology of testicular germ cell tumors. Clin Transl Oncol 8(12):846-50, 2006. e-Pub 2006. PMID: 17169757.
14. Felip E, Vilar E. The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy. Ann Oncol 17 Suppl 10:x108-12, 2006. e-Pub 2006. PMID: 17018710.

Other Articles

1. Martel-Martel A, Sinha KM, Vilar E Neoantigen Vaccines in Cancer Prevention. Cancer J 31(2), 2025. PMID: 40126885.
2. Bowen CM, Sinha KM, Vilar E Immunoprevention Strategies for Colorectal Cancer in Lynch Syndrome Carriers. Cancer J 30(5):352-356, 2024. PMID: 39312455.
3. Bowen CM, Demarest K, Vilar E, Shah PD Novel Cancer Prevention Strategies in Individuals With Hereditary Cancer Syndromes: Focus on BRCA1, BRCA2, and Lynch Syndrome. Am Soc Clin Oncol Educ Book 44(3):e433576, 2024. PMID: 38913968.
4. Bowen CM, Sinha KM, Vilar E Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes. Clin Colon Rectal Surg 37(3):146-156, 2024. PMID: 38606044.
5. Bolivar AM, Duzagac F, Sinha KM, Vilar E Advances in vaccine development for cancer prevention and treatment in Lynch Syndrome. Mol Aspects Med 93:101204, 2023. PMID: 37478804.
6. Serrano MJ, Garrido-Navas MC, Diaz Mochon JJ, Cristofanilli M, Gil-Bazo I, Pauwels P, Malapelle U, Russo A, Lorente JA, Ruiz-Rodriguez AJ, Paz-Ares LG, Vilar E, Raez LE, Cardona AF, Rolfo C, Liquid Biopsy ISO Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. Cancer Discov 10(11):1635-1644, 2020. PMID: 33037026.
7. Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, Consortium I, Odunsi A Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. J Immunother Cancer 8(1), 2020. PMID: 32554617.
8. Coletta AM, Peterson SK, Gatus LA, Krause KJ, Schembre SM, Gilchrist SC, Pande M, Vilar E, You YN, Rodriguez-Bigas MA, Strong LL, Lynch PM, Lu KH, Basen-Engquist K Energy balance related lifestyle factors and risk of endometrial and colorectal cancer among individuals with lynch syndrome: a systematic review. Fam Cancer 18(4):399-420, 2019. PMID: 31236808.
9. Diaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, Garcia-Donas J Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 88(1):154-67, 2013. PMID: 23562498.
10. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz-Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M, Marazuela M, Alvarez-Escola C, Castellano D, Vilar E, Jiménez-Fonseca P, Teulé A, Sastre-Valera J, Benavent-Viñuelas M, Monleon A, Salazar R Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21(9):1794-803, 2010. PMID: 20139156.
11. Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 14(2):221-32, 2007. PMID: 17639039.

Editorials

1. Colbert Maresso K, Maitra A, Hawk ET, Vilar E. From Premalignant Biology to Precision Interception: Connecting the Dots with a Curated Collection of Invited Articles. Cancer Prev Res (Phila) 16(7):365-367, 2023. PMID: 37403656.
2. Bansal A, Montgomery R, Vilar E. Can a Banana a Day Keep the Cancer Away in Patients with Lynch Syndrome?. Cancer Prev Res (Phila) 15(9):557-559, 2022. PMID: 36047056.
3. Willis JA, Overman MJ, Vilar E. Mismatch repair-proficient colorectal cancer: finding the right time to respond. Clin Cancer Res 25(17):5185-5187, 2019. PMID: 31263028.
4. Willis JA, Vilar E. Pharmacogenomics: Time to re-think its role in Precision Medicine. Ann Oncol 29(2):293-295, 2018. PMID: 29236957.
5. Barnett RM, Vilar E. Targeted Therapy for Cancer-Associated Fibroblasts: Are We There Yet?. J Natl Cancer Inst 110(1), 2018. PMID: 28922783.
6. Willis JA, Vilar E. Refining Prognosis in Early-Stage Colorectal Cancer: One or multiple genes at a time?. Ann Oncol 28(8):1686-1688, 2017. PMID: 28549076.
7. Vilar E, Stoffel EM. Universal Genetic Testing for Younger Patients With Colorectal Cancer. JAMA Oncol 3(4):448-449, 2017. PMID: 27978567.
8. Vilar E, Maresso KC, Hawk ET. Aspirin for Cancer Prevention: One Step Closer. JAMA Oncol 2(6):770-1, 2016. PMID: 26939883.
9. Colbert Maresso K, Vilar E, Hawk ET. Urinary PGE-M in Colorectal Cancer: Predicting More than Risk?. Cancer Prev Res (Phila) 7(10):969-72, 2014. PMID: 25070664.
10. Borras E, Taggart MW, Lynch PM, Vilar E. Establishing a Diagnostic Road Map for MUTYH-Associated Polyposis. Clin Cancer Res 20(5):1061-3, 2014. PMID: 24486588.
11. You YN, E V. Classifying MMR Variants: Time for Revised Nomenclature in Lynch Syndrome. Clin Cancer Res 19(9):2280-2, 2013. PMID: 23532885.
12. Vilar E, Tabernero J. Cancer: Pinprick diagnostics. Nature 486(7404):482-3, 2012. PMID: 22739312.
13. Vilar E, Tabernero J, Gruber SB. Micromanaging the classification of colon cancer: the role of the microRNAome. Clin Cancer Res 17(23):7207-9, 2011. PMID: 22019515.
14. del Campo JM, Vilar E. New challenges for molecular oncology in ovarian carcinoma. Med Clin (Barc) 128(1):15-7, 2007. PMID: 17266887.

Abstracts

1. Alves ALV, Martin AC, Silva VAO, da Silva Oliveira RJ, Teixeira SA, Romagnolo LGC, Reis MT, Duzagac F, Sinha K, Vilar E, Reis RM. Assessment of the anticancer potential of a natural compound euphol in colorectal cancer from in vitro and in vivo mouse models. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, 2023. e-Pub 2023.
2. Bowen CM, Deng, N, Reyes-Uribe L, Roger Parra E, Rocha P, Solis LM, Wistuba Ignacio I, Sepeda VO, Vornik L, Perloff M, Szabo E, Umar A, Sinha KM, Brown PH, Vilar E. Naproxen Chemoprevention Induces Proliferation of Cytotoxic Lymphocytes in Lynch Syndrome Colorectal Mucosa. AAP/ASCI/APSA Joint Meeting, 2023. e-Pub 2023.
3. Simmons K, Kee BK, Singh Raghav KP, Johnson B, Kopetz S, Willis JA, Dasari A, Vilar E, Ludford K, Parseghian CM, Lee ML, Le P, Shen JP, Overman MJ, Morris VK. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. ASCO Annual Meeting 2022 J Clin Oncol 40, 2022 (suppl 16; abstr 3585), 2022. e-Pub 2022.
4. Parseghian CM, Sun R, Woods MN, Napolitano S, Ashenaifi J, Willis JA, Nunez SK, Sorokin A, Kanikarla Marie P, Singh Raghav KP, Morris VK, Shen JP, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance mechanisms to anti-EGFR therapy in RAS/RAF wildtype colorectal cancer varies by regimen and line of therapy. 2022 ASCO Annual Meeting J Clin Oncol 40, 2022 (suppl 16; abstr 3554), 2022. e-Pub 2022.
5. Parseghian CM, Vilar E, Sun R, Eluri M, Morris VK, Johnson B, Morelli MP, Overman MJ, Willis JA, Huey R, Singh Raghav KP, Dasari A, Kee BK, Wolff RA, Shen JP, Kopetz S. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. 2022 ASCO Annual Meeting J Clin Oncol 40, 2022 (suppl 16; abstr 3520), 2022. e-Pub 2022.
6. Reyes Uribe L, Bowen CM, Evans K, Wu H, Duzagac F, Sinha K, Vilar E. Epigenetic intervention in the prevention of Lynch Syndrome Colorectal Cancer. 2022 AACR Annual Meeting Cancer Res (2022) 82 (12_supplement): 721, 2022. e-Pub 2022.
7. Parseghian C, Sun R, Napolitano S, Morris VK, Henry J, Willis J, Vilar E, Raghav K, Ang A, Kopetz S. Rarity of acquired mutations (MTs) after first-line therapy with anti-EGFR therapy (EGFRi). ASCO Annual Meeting 2021 J Clin Oncol 39, 2021 (suppl 15; abstr 3514), 2021. e-Pub 2021.
8. Ludford K, Raghav K, Blum Murphy M, Fleming N, Nelson D, Sandmin Lee M, Smaglo B, You YN, Tillman M, Kamiya-Matsuoka C, Thirumurthi T, Messick C, Johnson B, Vilar E, Dasari A, Thomas J, Chin Foo W, Qiao W, Kopetz S, Overman M. Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors. ASCO Annual Meeting 2021 J Clin Oncol 39, 2021 (suppl 15; abstr 2520), 2021. e-Pub 2021.
9. You YN, Rodriguez-Bigas M, Chang G, Bednarski B, Skibber J, Mork ME, Moskowitz J, Nguyen S, Thirumurthi T, Lynch PM, Kopetz S, Vilar E. Are current family-history based colorectal cancer screening guidelines adequate for early detection and potential prevention of young-onset cases?. ASCO Annual Meeting 2021 J Clin Oncol 39, 2021 (suppl 15; abstr 3549), 2021. e-Pub 2021.
10. Bowen CM, Chang K, Wu W, Bolivar A, Reyes L, Lizee G, Sinha K, Vilar E. Identification and Validation of Neoantigens for Developing a Preventive Vaccine for Mismatch-Repair Deficient Cancers Cancer Res (2021) 81 (13_Supplement): 1705, 2021. e-Pub 2021.
11. Reyes-Uribe L, Evans K, Kinnison J, Sepeda V, Weber D, Moskowitz J, Mork ME, Taggart MW, Thirumurthi S, Rodriguez-Bigas M, Lynch PM, You YN, Vilar E. Colorectal Cancer Surveillance Outcomes from an Institutional Longitudinal Cohort of Lynch Syndrome Patients. 2020 CGA Annual Meeting, 2020. e-Pub 2020.
12. Bommi P, Wu W, Reyes L, Thirumurthi S, Lynch P, Sinha K, Vilar E. Ex-vivo assessment of the effect of Simvastatin in intestinal epithelium of Lynch Syndrome patients. AACR 2020 Annual Virtual Meeting Cancer Res (2021) 81 (10): 2760–2773, 2020. e-Pub 2020.
13. Rajendran P, Ulusan A, Dashwood WM, Kapoor S, Mohammed A, Sei S, Rashid A, Brown PH, Vilar E, Dashwood RH. Optimization of dosing regimens of sulindac in combination with erlotinib for small intestine and colorectal cancer prevention. 2020 AACR Virtual Annual Meeting Cancer Res (2020) 80 (16_supplement): 21, 2020. e-Pub 2020.
14. Reyes-Uribe L, Wu W, Gelincik O, Bommi P, Francisco-Cruz A, Solis L, Lynch P, Lim R, Stoffel E, Kanth P, Samadder N, Mork M, Taggart M, Milne G, Marnett L, Vornik L, Liu D, Revuelta M, Chang K, You Y, Kopelovich L, Wistuba I, Lee J, Sei S, Shoemaker R, Szabo E, Richmond E, Umar A, Perloff M, Brown P, Lipkin S, Vilar, E. Naproxen Chemoprevention Promotes Immune Activation In Lynch Syndrome Colorectal Mucosa. 2020 AACR Virtual Annual Meeting Cancer Res (2020) 80 (16_Supplement): CT111, 2020. e-Pub 2020.
15. Vilar E, Burke C, Correa M, Dekker E, Grandval P, Katona B, Llor X, Riegert-Johnson D, Saurin J, Stanich P, Sussman D, Weinberg D, Attiyeh E, Joseph D, Raybold K, Borzillo G, Prior T, Smith S, Xie H, Bachman K, Infante J, Samadder N. Session VPO.CT07.01 - Phase I Trials in Progress CT236 - A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the e􀃞cacy of guselkumab in subjects with familial adenomatous polyposis. 2020 AACR Virtual Annual Meeting Cancer Res (2020) 80 (16_Supplement): CT236, 2020. e-Pub 2020.
16. Peacock O, Yang Y, Thirumurthi S, Nguyen STN, Lum P, Rodriguez-Bigas MA, Bednarski BK, Messick C, Skibber JM, Chang GJ, Vilar E, You YN. Metachronous colorectal pathology among survivors of young-onset colorectal cancer: Implications for postresection colonoscopic surveillance. 2020 Gastrointestinal Cancers Symposium J Clin Oncol 38, (suppl 4; abstr 64), 2020. e-Pub 2020.
17. Willis JA, Chen JS, Mork MM, Chang K, Kinnison J, Rodriguez-Bigas MA, Thirumurthi S, Borras E, Taggart MW, Lynch PM, You YN, Huff C, Vilar E. Exploring the genetic basis of Lynch-like syndrome through paired germline and tumor exome sequencing. 2019 CGA Annual Meeting, 2019. e-Pub 2019.
18. Reyes L, Evans K, Kinnison J, Sepeda V, Weber D, Moskowitz J, Mork ME, Taggart MW, Thirumurthi S, Rodriguez-Bigas MA, Lynch PM, You YN, Vilar E. Using Research Electronic Data Capture (REDCap) for Supporting a Longitudinal Cohort Study of Hereditary Cancer Patients. 2019 CGA Annual Meeting, 2019. e-Pub 2019.
19. Wang C, Gelincik O, Maruvka Y, Ibrahim H, Wu C, Hacohen N, Stadler Z, Vilar E, Getz G, Lipkin SM. Lynch syndrome Colorectal Cancer Immunoprevention using Recurrent Neoantigen Peptide Vaccination. 2019 CGA Annual Meeting, 2019. e-Pub 2019.
20. Mork MM, Bannon SA, Moskowitz J, Lynch P, Rodriguez-Bigas MA, Thirumurthi S, You YN, Vilar E. Outcomes of Polyposis Genetic Testing in Patients Previously Treated for Hematologic Malignancies. 2019 CGA Annual Meeting, 2019. e-Pub 2019.
21. Wu W, Reyes L, Chang K, Stoffel EM, Lim R, Kanth P, Lynch PM, Samadder N, Milne GL, Marnett LJ, Sepeda V, You YN, Vornik L, Lee JJ, Richmond E, Perloff M, Brown PH, Lipkin SM, Vilar E. Transcriptomic profiling and deconvolution for biomarker identification and immune cell infiltration estimation in colon mucosa of Lynch syndrome patients from a phase Ib chemo-preventive trial of naproxen. American Society of Human Genetics 2019 Annual Meeting, 2019. e-Pub 2019.
22. Gray SB, Raveendran M, Dray BK, Harris RA, Benavides F, Ozirmak N, Abee CR, Vilar E, Rogers J. A spontaneous rhesus macaque model of heritable colorectal cancer associated with mutations in DNA Mismatch Repair (MMR) genes: An improved animal model of Lynch syndrome in humans. American Society of Human Genetics 2019 Annual Meeting, 2019. e-Pub 2019.
23. Jakubek YA, Chang K, Sivakumar S, Yu Y, Fowler J, Huff CD, Vilar E, Kadara H, Scheet PA. Point mutation and somatic copy number analysis reveals drivers of clonal expansions in normal tissue adjacent to head and neck squamous carcinoma. American Society of Human Genetics 2019 Annual Meeting, 2019. e-Pub 2019.
24. Chakravarti D, Multani A, Dey P, Hu B, Zhao D, Chang K, Xizeng M, Wang G, Terranova C, Liao W, Spring D, Hou P, Zhang J, Okhuysen P, Vilar E, Estes MK, Blutt S, Wang A, DePinho R. Telomere dysfunction is a driver of inflammatory bowel disease 79(13), 2019. e-Pub 2019.
25. Ulusan A, Rajendran P, Dashwood W, Mohammed A, Sei S, Brown PH, Vilar E, Dashwood R. Optimizing erlotinib plus sulindac dosing regimens in a preclinical model of FAP Cancer Res (2019) 79 (13_Supplement): 5074, 2019. e-Pub 2019.
26. Johnson GS, Rajendran P, Li L, Chen YS, Mohaiza Dashwood W, Nguyen N, Ulusan AM, Ertem F, Zhang M, Sun D, Huang Y, Wang S, Leung HE, Lieberman D, Beaver LM, Ho E, Bedford MT, Chang K, Vilar E, Dashwood RH. CCAR2 acetylation establishes a BET/BRD9 acetyl switch in response to combined deacetylase and bromodomain inhibition Cancer Res (2019) 79 (13_Supplement): 2614, 2019. e-Pub 2019.
27. Willis JA, Mork ME, Chang K, Kinnison J, Rodriguez-Bigas MA, Thirumurthi S, Borras E, Taggart MW, Lynch PM, You YN, Vilar E. Exploring the genetic basis of Lynch-like syndrome through paired germline and tumor exome sequencing. 2019 ASCO Annual Meeting J Clin Oncol 37, 2019 (suppl; abstr 3592), 2019. e-Pub 2019.
28. Willis J, Mork ME, Chang K, Kinnison J, Rodriguez-Bigas MA, Thirumurthi S, Borras E, Taggart M, Lynch PM, You YN, Vilar E. Exploring the genetic basis of Lynch-like syndrome through paired germline and tumor exome sequencing. ASCO Annual Meeting 2019, Chicago, IL, 2019. e-Pub 2019.
29. Montiel MF, Quesada PPR, Dunseith M, Cazacu I, Luzuriaga A, Dong W, Bannon SA, Mork ME, Feng L, You YN, Vilar E, Arun B, Brown P, Kim MP, Katz M, Maitra A, Bhutani MS, McAllister F. New onset diabetes as a predictive factor of focal lesions in the pancreas in a high-risk screening program. ASCO Annual Meeting 2019, Chicago, IL, 2019. e-Pub 2019.
30. Thirumurthi S, Pande M, Lim P, Bannon S, Mork ME, Rodriguez-Bigas MA, You YN, Vilar E, Lynch PM. How to Create an Electronic Database for HNPCC (Lynch Syndrome) from Existing Software Programs: MD Anderson Cancer Center HNPCC Surveillance Outcomes, A Step Towards Establishing Quality Metrics for High Risk Cancer Patients. Gastrointestinal Endoscopy 87(6):AB493-AB494, 2018. e-Pub 2018.
31. Montiel MF, Quesada PR, Dunseith M, Vilar E, Bhutani MS, Kim MP, Katz MHG, Maitra A, Mork ME, Arun B, Bannon SA, McAllister F. Early outcomes of a high-risk cohort in pancreatic cancer surveillance. 2018 ASCO Annual Meeting J Clin Oncol 36, 2018 (suppl; abstr e16258), 2018. e-Pub 2018.
32. Lima Pereira AA, Lam M, KanikarlaMarie P, Singh Raghav KP, Morris VK, Brown H, Windham J, Duose DY, Overman MJ, Vilar E, Wistuba II, Kipp P, Janku F, Sinha S, Kopetz S. Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC). 2018 ASCO Annual Meeting J Clin Oncol 36, 2018 (suppl; abstr 3533), 2018. e-Pub 2018.
33. Lima AA, Loree JM, Davis JS, Lam M, Morris V, Overman MJ, Raghav K, Kee BK, Fogelman D, Vilar E, Shureiqi I, Eng C, Manuel S, Crosby S, Wolff RA, Lanman RB, Talasaz A, Janku F, Kopetz S. Predictors for detecting Circulating tumor DNA (ctDNA) in Metastatic Colorectal Cancer (mCRC). ASCO Meeting Abstracts 2018 Gastrointestinal Cancers Symposium:634, 2018. e-Pub 2018.
34. Willis JA, Morelli MP, Morris VK, Loree J, Lam M, Lime AA, Raghav K, Kee BK, Vilar E, Eng C, Manuel S, Crosby S, Wolff RA, Lanman RB, Talasaz A, Janku F, Overman MJ, Kopetz S. Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2018 Gastrointestinal Cancers Symposium:616, 2018. e-Pub 2018.
35. Chang K, Taggart MW, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet PA, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister FM, Vilar E. Lynch Syndrome Premalignancy Upregulates Immune Checkpoints Independently From Neoantigen and Mutational Rates. AACR Annual Meeting 2018, Chicago, IL, 2018. e-Pub 2018.
36. Uribe LR, Lin R, Stoffel EM, Samadder NJ, Lynch PM, Kanth P, Milne GL, Marnett LJ, Sepeda V, Liu DD, You YN, Vornik LA, Lee JJ, Richmond E, Umar A, Perloff M, Lipkin SM, Brown PB, Vilar E. A phase Ib biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer. AACR Annual Meeting 2018, Chicago, IL Cancer Res (2018) 78 (13_Supplement): CT065, 2018. e-Pub 2018.
37. You YN, Cuddy A, Sammour T, Hu C, Chang G, Eng C, Vilar E. American Society of Colon & Rectal Surgeons Annual Scientific Meeting, 2017. e-Pub 2017.
38. Borras E, Chang K, San Lucas A, Masand G, Delgado Amador A, Fowler J, Davies GE, Ehli EA, You YN, Lynch PM, Hawk ET, Capella G, Scheet PA, Vilar E. High-depth sequencing reveals the presence of multi-clonality in colorectal premalignancy. 2017 AACR Annual Meeting Cancer Res (2017) 77 (3_Supplement): A02, 2017. e-Pub 2017.
39. Ertem FU, Zhang W, Chang K, Dashwood WM, Rajendran P, Sun D, Abudayyeh A, Abdulrahim M, Vilar E, Dashwood RH. Prevention by tolfenamic acid and characterization of the molecular targets in Pirc and FAP colorectal adenomas. 2017 AACR Annual Meeting Cancer Res (2017) 77 (13_Supplement): 2229, 2017. e-Pub 2017.
40. Ornelas A, Zacharias-Millward N, Davis J, Menter D, Hawke D, Bhattacharya, Vilar E, Millward S. Hyperpolarization of 13C-Aspirin and Monitoring of Reactivity by Magnetic Resonance Spectroscopy 58(abstr 326), 2017. e-Pub 2017.
41. Foo WC, Overman M, Vilar E, Abraham S, Taggart MW. High level microsatellite instability in appendiceal carcinomas. United States and Canadian Academy of Pathology, 2017. e-Pub 2017.
42. Sarshekeh AM, Overman M, Kee B, Fogelman D, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff R, Patel K, Luthra R, Shaw K, Eng C, Maru D, Routbort M, Meric-Bernstam F, Kopetz S. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. ASCO Meeting Abstracts:565, 2016. e-Pub 2016.
43. Vilar E, Stoffel E, Lim R, Lynch P, You YN, Lipkin S, Vornik L, Lee J, Perloff M, Brown PB. A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch Repair Deficient Colorectal Cancer 26(suppl_4):iv90, 2015. e-Pub 2015.
44. Morris V, Morelli M, Janku F, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Garrett C, Raghav K, Eng C, Manuel S, Wolff R, Eltoukhy H, Lanmen R, Talasaz A, Kopetz S. Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. J Clin Oncol 33, abstr 3601, 2015. e-Pub 2015.
45. Lee M, Clarke C, Jiang Z, Manym G, Tian F, Lu Y, Broom B, Menter D, Vilar E, Shureiqi I, Raghav K, Eng C, Chang G, Simon I, Bernards R, Mills G, Overman M, Maru D, Kopetz S. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis. J Clin Oncol 33, abstr 3612, 2015. e-Pub 2015.
46. Morelli M, Overman M, Kee B, Vilar E, Morris V, Fogelman D, Janku F, Garrett C, Shureiqi I, Raghav K, Eng C, Manuel S, Wolff R, Eltoukhy H, Lanman R, Talasaz A, Kopetz S. Predictors of clonal evolution in metastatic colorectal cancer patients. J Clin Oncol 33, abstr 3604, 2015. e-Pub 2015.
47. Overman M, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Kopetz S. A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33, abstr e14700, 2015. e-Pub 2015.
48. Borras E, San Lucas A, Chang K, Bhatia G, Wu H, Fowler J, You YN, Lynch PM, Taggart MW, Hawk ET, Capella G, Scheet P, Vilar E. Characterizing the genomic landscape of premalignant colorectal polyps using next-generation sequencing. AACR 2015 Annual Meeting, Philadelphia, PA Cancer Res (2015) 75 (15_Supplement): 4806, 2015. e-Pub 2015.
49. You YN, Vilar E, Cuddy A, Wu C, Lynch PM, Eng C, Rodriguez - Bigas MA, Chang GJ. Are young adults with colorectal cancer doing enough to stay healthy?. 2015 AACR Annual Meeting, Philadelphia, PA, 2015. e-Pub 2015.
50. Morelli MP, Overman M, Vilar E, Morris V, Fogelman D, Shureiqi I, Garret C, Kanwal R, Eng C, Kee B, Manuel S, Wolff R, Sebisanovic D, Sew L, Zapanta A, Shiller B, Mei G, Eltoukhy H, Talasaz A, Kopetz S. Prospective clinical application of circulating cell-free DNA sequencing in metastatic colorectal cancer. AACR 2015 Annual Meeting, Philadelphia, PA, 2015. e-Pub 2015.
51. Chang K, Borras E, San Luca A, Fowler J, Hawk E, Capella G, Scheet P, Vilar E. Genomic analysis reveals evidence of clonality in premalignant colonic polyps. AACR Annual Meeting, Philadelphia, PA Cancer Res (2015) 75 (15_Supplement): 1087, 2015. e-Pub 2015.
52. Clarke C, Lee MS, Manyam GC, Jiang ZQ, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar E, Raghav K, Eng C, Chang GJ, Overman MJ, Maru DM, Kopetz S. Proteomic features of colorectal cancer independently predict relapse-free survival. J Clin Oncol 33, abstr 616, 2015. e-Pub 2015.
53. You YN, Chang K, Chen K, Mehdizadeh A, Cuddy A, Lieu CH, Shaw KR, Vilar E, Eng C. Somatic mutations in young-onset colorectal cancer unrelated to hereditary syndromes: a comparative study using high-depth targeted exome sequencing. J Clin Oncol suppl 3; abstr 623, 2015. e-Pub 2015.
54. Pande M, Borras E, You YN, Cuddy A, Bannon SA, Mork ME, Rodriguez-Bigas MA, Lynch PM, Vilar E. Variants of unknown significance in DNA mismatch repair genes: results from a hospital based hereditary cancer registry. 2015 InSight Meeting, Basic Science and Molecular Biology, 2015. e-Pub 2015.
55. Lee MS, Clarke C, Jiang ZQ, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar E, Shureiqi I, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Mills GB, Overman MJ, Maru DM, Kopetz S. Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations. J Clin Oncol 33, abstr 580, 2015. e-Pub 2015.
56. You YN, Vilar E, Cuddy A, Wu C, Lynch PM, Eng C, Rodriguez-Bigas MA, Chang GJ. Are young adults with colorectal cancer doing enough to stay healthy?. AACR Annual Meeting 2015, Philadelphia, PA, 2015. e-Pub 2015.
57. You YN, Chang K, Chen K, Mehdizadeh A, Cuddy A, Lieu C, Meric-Bernstam F, Shaw-Miller K, Vilar E, Eng C. Somatic mutations in young-onset colorectal cancer unrelated to hereditary syndromes: A comparative study using high-depth targeted exome sequencing. Gastrointestinal Cancers Symposium Annual Meeting, San Francisco, CA, 2015. e-Pub 2015.
58. You YN, Chang K, Chen K, Mehdizadeh A, Cuddy A, Lieu C, Meric-Bernstam F, Shaw-Miller K, Vilar E, Eng C. Somatic mutations in young-onset colorectal cancer unrelated to hereditary syndromes: A comparative study using high depth targeted exome sequencing. 2015 Gastrointestinal Cancers Symposium, 2015. e-Pub 2015.
59. You NY, Cuddy A, Peterson S, Vilar E, Zorzi D, Mork M, Bannon S, Lynch PM, Rodriguez-Bigas MA. High Prevalence Of Modifiable Lifestyle Risk Factors For Colorectal Cancer Among Lynch Syndromes Patients. 18th Annual Meeting Collaborative Group of the Americas Inherited Colorectal Cancer, New Orleans, LA, 2014. e-Pub 2014.
60. Mork M, You NY, Ying J, Lynch P, Rodriquez-Bigas MA, Vilar E. Elucidating the impact of Hereditary Colorectal Cancer Syndromes in Adolescents and Young Adults ages 35 and under diagnosed with Colorectal Cancer. 18th Annual Meeting Collaborative Group of the Americas Inherited Colorectal Cancer, New Orleans, LA, 2014. e-Pub 2014.
61. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton L, Manuel S, Garrett CR, Vilar E, Dennis CS, Shureiqi I, Mills GB, Shaw KR, Hamilton SR, Wolff RA, Meric-Bernstam F, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. J Clin Oncol 32(5s), 2014. e-Pub 2014.
62. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton L, Manuel S, Garrett CR, Vilar E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastics colorectal cancer trials: The ATTACC program experience 32(suppl 3; abstr 450), 2014. e-Pub 2014.
63. Lima Pereira AA, De Mendonga Rego JF, Morris VK, Overman MJ, Cathy Eng C, Garrett CR, Ferrarotto R, Lee MS, Jiang Z, Hoff PM, Vauthey JN, Vilar E, Maru DM, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer 32(suppl 3; abstr 494), 2014. e-Pub 2014.
64. Hassabo HM, Sahin IH, Al Kazmi SM, Al Mutar SS, Gomes DBD, Pini TM, Vilar E, Dasari A, Kopetz S, Overman MJ, Eng C, Kee BK, Vauthey JN, Hassan M, Garrett CR. Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS) 32(suppl 3; abstr 473), 2014. e-Pub 2014.
65. Lee MS, Overman MJ, Maru DM, Jiang Z, Sl M, Eng C, Kee BK, Fogelman DR, Garrett CR, Advani SM, Vilar E, Shureiqi I, Wolff RA, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. J Clin Oncol 32(5s), 2014. e-Pub 2014.
66. Morelli MP, Overman MJ, Vilar E, Morris VK, Shureiqi I, Garrett CR, Fogelman DR, Singh Raghav KP, Kee BK, Deaton L, Eng C, Wolff RA, Sebisanovic D, Siew L, Zapanta A, Mei G, Schiller B, Eltoukhy H, Talasaz A, Kopetz S. Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients. J Clin Oncol 32(5s), 2014. e-Pub 2014.
67. Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, Dasari A, Singh Raghav KP, Vilar E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbort M, Maru DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol 32(5s), 2014. e-Pub 2014.
68. San Lucas FA, Fowler J, Kopetz S, Vilar E, Scheet P. Drug repositioning with a bioinformatics platform that integrates the TCGA, cMap, and CCLE. 2014 AACR Annual Meeting, San Diego, CA, 2014. e-Pub 2014.
69. Borras-Flores E, Calhoun K, Bhatia G, Wu H, Vilar E. PIK3CA mutation status is not involved in the response of nonsteroidal anti-inflammatory drugs in colorectal cancer cell lines. AACR Annual Meeting, San Diego, CA, 2014. e-Pub 2014.
70. You YN, Bednarski B, Vilar-Sanchez E, Chang GJ, Feig BW, Skibber JM, Ellis L, Bannon S, Mork M, Lynch PM, Rodriguez-Bigas MA. Lynch or not Lynch: Clinical translation of findings from a prospective surgeon-triggered program to universally screen for mismatch-repair deficiency in patients with colorectal cancer. American Society of Colon & Rectal Surgeons Annual Meeting, Hollywood, FL, 2014. e-Pub 2014.
71. Vilar E, You YN, Vornik LA, Stoffel EM, Lim RM, Lipkin SM, Perloff M, Brown P. A phase lb biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer. AACR: Frontiers in Cancer Prevention Research:C52, 2013. e-Pub 2013.
72. Vilar E, Bannon S, Mork M, Cuddy A, Lynch PM, You YN. Colorectal Cancer in Lynch Syndrome: No Age Discrimination. 2013 INSIGHT Meeting, 2013. e-Pub 2013.
73. You NY, Chang GJ, Bannon S, Mork M, Vilar E, Cuddy A, Lynch PM, Rodriguez-Bigas MA. Lynch Sydrome Associated Rectal Cancer: Characteristics and Outcomes. 63rd Annual Meeting of the Society of Pelvic Surgeons, 2013. e-Pub 2013.
74. Morelli MP, Overman MJ, Dasari A, Ali Kazmi SM, Vilar E, Eng C, et al. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. J Clin Oncol 31:3512, 2013. e-Pub 2013.
75. Vilar E, Wu W, Bhatia G, Cuddy A, Mork MM, Bannon SA, et al. Can microsatellite status of colorectal cancer (CRC) be reliably assessed after neoadjuvant therapy?. J Clin Oncol 31:1525, 2013. e-Pub 2013.
76. You YN, Vilar E, Slack R, Chang GJ, Nguyen STN, Cuddy A, et al. Lynch syndrome testing in ethnically diverse patients: Mutation spectrum and performance of prediction models. J Clin Oncol 31:1546, 2013. e-Pub 2013.
77. San Lucas FA, Kopetz S, Scheet PA, and Vilar E. Discovering new therapies for BRAF mutat-like colorectal cancers. J Clin Oncol 31:3623, 2013. e-Pub 2013.
78. Morris VK, Overman MJ, Eng C, Vilar E, Morelli M, Jiang Z, et al. Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. J Clin Oncol 31:3632, 2013. e-Pub 2013.
79. You NY, Vilar E, Taggart MW, Mork ME, Bannon SA, Lynch PM, Rodriguez-Bigas MA. DNA mismatch repair protein immunohistochemistry in colorectal cancer after neoadjuvant therapy: The pre-treatment biopsy should be the standard. 16th Annual Collaborative Group of Americas on Inherited Colorectal Cancer, Boston, MA, 2012. e-Pub 2012.
80. Overman MJ, Kopetz S, Wong S, Tie J, Kosmider S, Jacob A, Vilar E, Gibbs P, Desai J, Tran B. Survival Outcomes in Metastatic Colorectal Cancer (CRC) with High- Level Microsatellite Instability (MSI-H). ESMO Annual Meeting 2012 Vienna, Austria, 2012. e-Pub 2012.
81. San Lucas FA, Scheet P, Vilar E. Clinically assessing colorectal cancers with next-generation sequencing. ICSB: The 13th International Conference on Systems Biology Toronto, Canada, 2012. e-Pub 2012.
82. Diaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, Garcia-Donas J. Mismatch Repair Status As A Prognostic Marker In Endometrial Cancer. British Gyanecological Cancer Society Annual Scientific Meeting, The Queen Elizabeth II Conference Centre London, UK, 2012. e-Pub 2012.
83. Vilar E, Chow A, Raskin L, Iniesta MD, Mukherjee B, Gruber SB. Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer. J Clin Oncol (Meeting Abstracts) 11028, 2009. e-Pub 2009.
84. Raskin L, Johnson TM, Fullen DR, Giordano TJ, Vinco M, Mukherjee B, Ahn J, Vilar E, Gruber SB. HMGA2 is a novel prognostic factor in melanoma. AACR Meeting Abstracts:2604, 2009. e-Pub 2009.
85. Vilar E, Mukherjee B, Rennert G, Gruber SB. Discovering new drugs to target microsatellite instable (MSI) colorectal cancer (CRC) using the Connectivity Map (CMap). ASCO Meeting Abstracts:11087, 2008. e-Pub 2008.
86. Capdevila-Castillon J, Crespo G, Garcia-Carbonero R, Vilar E, Jimenez-Lacave A, del Prado MPM, et al. Results of the Gastroenteropancreatic NETs Spanish Registry in the 2001-2009 Period. 6th Annual Conference of the European-Neuroendocrine-Tumor-Society:19, 2007. e-Pub 2007.
87. Lopez-Martin A, Paz-Ares L, Calvo E, Castellano D, Valverde C, Neciosup S, Vilar E, San Antonio B, Garcia-Ribas I, Cortes-Funes H, and Bellmunt J. Phase I study of bi-weekly pemetrexed (P) plus cisplatin (C) in patients with advanced cancer. ASCO Meeting Abstracts:2580, 2007. e-Pub 2007.
88. Martinez P, Saura C, Perez Garcia JM, Vilar E, Gomez P, Casado E, et al. [Analysis of the accuracy of the Family History in Patients diagnosed with Breast or Colon Cancer]. XI National Congress of the Spanish Society of Medical Oncology:P-20, 49, 2007. e-Pub 2007.
89. Garcia-Carbonero R, Vilar E, Alonso V, Martinez del Prado MP, Sevilla I, Crespo G, et al. [Spanish National Tumor Registry of Neuroendocrine Gastroenteropancreatic Tumors: Epidemiology, Patterns of Clinical Practice and Long-Term Survival in our Environment]. XI National Congress of the Spanish Society of Medical Oncology:O-46, 26, 2007. e-Pub 2007.
90. Garcia-Carbonero R, Vilar E, Alonso V, Martinez del Prado M, Sevilla I, Crespo G, et al. Patterns of care and outcome of patients with gastroenteropancreatic neuroendocrine tumors (GNETs): Results from a Spanish multi-center hospital-based tumor registry. ASCO Meeting Abstracts:15110, 2007. e-Pub 2007.
91. Salazar R, Vilar E, Garcia-Carbonero R, Alonso V, Martinez del Prado M, Sevilla I, et al. 2001-2007 Results of the gastroenteropancreatic NETs Spanish Registry. 4th Annual ENETS Conference, 2007. e-Pub 2007.
92. Vilar E, Scaltriti M, Saura C, Guzman M, Macarulla T, Arribas J, et al. Microsatellite instability (MSI) due to mutation or epigenetic silencing is associated with increased cytotoxicity to irinotecan (CPT-11) in human colorectal cancer (CRC) cell lines. ASCO Meeting Abstracts(10527), 2007. e-Pub 2007.
93. Saura C, Dominguez R, Fortuny D, Vilar E, Sabadell D, Cordoba O, et al. [Breast Cancer Early Diagnosis Program in High-Risk Females: Pilot Experience of Surveillance Using Mammography and Breast MRI]. XI National Congress of the Spanish Society of Medical Oncology:O-14, 0, 2007. e-Pub 2007.
94. Vilar E, Saura C, Scaltriti M, Guzman M, Balmana J, Macarulla T, et al. Microsatellite instability (MSI) due to mutation or epigenetic silencing is associated with increased cytotoxicity to irinotecan (CPT-11) in human colorectal cancer (CRC) cell lines. Gastrointestinal Cancers Symposium, 2007. e-Pub 2007.
95. Saura C, Vilar E, Cortes J, Bellet M, Ocana A, Gomez P, et al. Pegfilgrastim induces elevation of serum CA 15-3 in breast carcinoma patients after receiving dose-dense adjuvant chemotherapy. ASCO Meeting Abstracts:8595, 2006. e-Pub 2006.
96. Salazar R, Vilar E, Martínez M, Sastre J, Alonso V, Sevilla M, et al. Preliminary results 2001 – 2005 of the Spanish Registry of the gastroenteropancreatic NETs. 2005 of the Spanish Registry of the gastroenteropancreatic NETs. 3rd Annual ENETS Conference; Prague. Czech Republic, 2006. e-Pub 2006.
97. Gomez P, Vilar E, Saura C, Cortes J, Ocana A, Bellet M, et al. Feasibility of pegfilgrastim as haematopoietic support for dose-dense every-2-week adjuvant chemotherapy in breast cancer. ASCO Meeting Abstracts:18606, 2006. e-Pub 2006.
98. Vilar E, Martinez M, Alonso V, Sevilla M, Sastre J, Castellano D, et al. Influence of first line treatment in the 5 (5yS) and 10-year (10yS) survival outcomes of patients with gastroenteropancreatic neuroendocrine tumors (GNETs): 2001-2005 Spanish task force GNET group. ASCO Meeting Abstracts:14058, 2006. e-Pub 2006.
99. Salazar R, Vilar E, Sevilla I, Sastre J, Villabona C, Alonso V. Preliminary results from the Spanish Registry of gastroenteropancreatic neuroendocrine tumors 2001 – 2005. X Congreso Nacional SEOM, Saragoza, Spain, 2005. e-Pub 2005.
100. Cedres S, Felip E, Prat A, Rojo F, Majo J, Pallisa E, de Gracia J, Vilar E, Parera M, and Baselga J. Comparison of Epidermal Growth Factor Receptor (EGFR) and downstream markers expression in samples from Non-Small-Cell Lung Cancer (NSCLC) patients, at diagnosis and after progression following platinum-based chemotherapy. Ann Oncol:ix245–ix59, 2005. e-Pub 2005.
101. Tabernero J, Casado E, Macarulla T, Ramos J, Martinelli E, Gómez P, Roca JM, Vilar E. Target drug therapies against the epithelial growth factor receptor in metastatic colon cancer. V Congreso Nacional FESEO; Valencia. Spain, 2004. e-Pub 2004.
102. Vilar-Sanchez E, Lee C, Sukumar J, Strong L, Peterson S, Arun B, Baum M, Basen-Engquist K. Optimization of Mhealth Behavioral Intervention for Families with Hereditary Breast and Ovarian Cancers: The Health4families Study. ACSM 25 Annual Meeting, Atlanta, GA.

Book Chapters

1. Chang, K, McAllister, F, Vilar Sanchez, E. Transcriptomic-Assisted Immune and Neoantigen Profiling in Premalignancy, 95-105, 2022.
2. Thirumurthi S, Vilar E, Lynch P. Hereditary Gastrointestinal Cancers. In: Textbook of Gastrointestinal Oncology. Springer, Cham, 595-611, 2019.
3. Vilar E, Salazar R, Tabernero J. Medical Oncology Management of Hereditary Colorectal Cancer. In: Hereditary Colorectal Cancer: Genetic Basis and Clinical Implications. Springer Nature, 401-416, 2018.
4. Barnett RM, Borras E, Samadder NJ, Vilar E. Chemoprevention in Hereditary Colorectal Cancer Syndromes. In: Hereditary Colorectal Cancer: Genetic Basis and Clinical Implications. Springer Nature, 349-366, 2018.
5. Reyes JM, Vilar E. Epidemiology and Prevention. In: Medicina Interna Farreras. 18. Elsevier, 1084-85, 2016.
6. Vilar E. Colorectal Cancer. In: Medicina Interna Farreras. 18. Elsevier, 1101-3, 2016.
7. Mork M, Vilar E. MUTYH-Associated Polyposis. In: Intestinal Polyposis Syndromes Diagnoses and Management. Springer International Publishing, 25-32, 2016.
8. Bailey CE, Vilar E, You YNY. Adjuvant and Neoadjuvant Management of Cancer of the Colon and Rectum. In: ACS Surgery, Principles and Practice. Decker Intellectual Properties, 2014.
9. Maresso KC, Patterson S, Vilar E, Hawk E. Prevention and Screening: risk factors, screening, and chemoprevention. In: Cancers of the Colon and Rectum: A Multidisciplinary Approach to Diagnosis and Management. Demos Medical Publishing, 2013.
10. Vilar E, Zalupski MM. Oncology Boards Flash Review. In: Gastric Cancer. Demos Medical Publishing, LLC, 221, 2013.
11. Vilar E, Zalupski MM. Gastric cancer. In: Tumor Board Review. Demos Medical, 72-80, 2012.
12. Saura C, Vilar E, Macarulla T, Casado E, Ramos FJ, Capdevila J, Taberno J. Chapter 4: Targeted therapies in gastroesophageal cancer: present and future. In: Gastric Cancer Research Trends. Nova Science Publishers, 107-127, 2007.
13. Vilar E, Sastre J, Tabernero J. [Chemotherapy and biologic treatments of gastrointestinal neuroendocrine tumors]. In: [Handbook of diagnosis and treatment of Neuroendocrine Tumors. GETNE Group]. GETNE Group, 2006.
14. Carulla J, Vilar E, Saura C. [Assessment of nutritional status]. In: Anorexia and Cachexia Handbook. SEOM, 107 – 120 (chapter in spanish), 2005.
15. Bowen CM, Sinha K, Vilar E. Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes. Clinics in Colon and Rectal Surgery. In: Thieme Medical Publishers.

Letters to the Editor

1. You YN, Rodriguez-Bigas MA, Das P, Healy M, Chiang YJ, George T, Vilar E. Comment on "A National Cancer Database Analysis of Microsatellite Instability and Pathologic Complete Response in Locally Advanced Rectal Cancer". Ann Surg 274: E197-E198, 2021.
2. Mork ME, You YN, Vilar E. Reply to L.B. Saltz. J Clin Oncol 34: 1560-1, 2016.
3. Vilar E, Balmaña J, Espín E. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer 106: 2528-9; author reply 2529, 2006.
4. Vilar E, Tabernero J, Casado E, Macarulla T, Ramos FJ, Martinelli E, Saura C. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 28: 424, 2005.